0
Obstructive Lung Diseases |

Twelve-Week Clinical Outcomes Following an Emergency Department Asthma Visit

Robert Silverman*, MD; Keunpyo Kim, PhD; Joseph Parker, MD; Kimmie McLaurin, MA; Xiao Tu, PharmD; Nestor Molfino, MD
Author and Funding Information

MedImmune LLC, Gaithersberg, MD


Chest. 2012;142(4_MeetingAbstracts):730A. doi:10.1378/chest.1373231
Text Size: A A A
Published online

Abstract

SESSION TYPE: Asthma Predictors and Outcomes

PRESENTED ON: Wednesday, October 24, 2012 at 02:45 PM - 04:15 PM

PURPOSE: Relapse, defined as the need for emergent or urgent care following an emergency department (ED) visit, is common in subjects with asthma even following a course of systemic corticosteroids. Although 25% of adults relapse within 4 weeks, it is not clear whether this represents relapse of the acute episode or chronic recidivism from persistently uncontrolled asthma. To better define the clinical course following an asthma exacerbation resulting in an ED visit, we measured lung function and the frequency of exacerbations during the subsequent 12 weeks.

METHODS: Data were analyzed from the standard care group of a multicenter study of adult subjects presenting to the ED with an asthma exacerbation, having an FEV1 <70% predicted following bronchodilator therapy, and having ≥1 exacerbation within the previous year. Subjects were treated with a 7-day course of systemic corticosteroids and provided with a prescription for 12 weeks of inhaled corticosteroids at discharge. Subjects returned at weeks 1, 6, and 12 for evaluation.

RESULTS: Baseline characteristics of 36 subjects were an average age of 36 years; 28 (78%) were women, and 25 (69%) were African American. The number of ED visits in the prior year averaged 5.9 (median 3.0), and 9 subjects (25%) had a lifetime history of endotracheal intubation for asthma. The baseline percent-predicted FEV1 was 57% after initial ED bronchodilator therapy, 66% at week 1, and remained unchanged (67%) at week 12. A total of 31 exacerbations were observed in 14 (39%) of 36 subjects by week 12. Of those, 6% occurred at week 1, 45% between weeks 2 to 6, and 48% between weeks 7 to 12. The weighted exacerbation rate through week 12 was 3.59 exacerbations/subject/year (95% CI 2.44, 5.10).

CONCLUSIONS: Twelve weeks following an ED visit, asthma remained poorly controlled and exacerbations were common, despite prescription of controller therapy.

CLINICAL IMPLICATIONS: This study identifies a population that requires better management strategies to achieve long-term asthma control and prevent emergent visits following an ED visit.

DISCLOSURE: Robert Silverman: Other: Prinicipal investigator in a clinical trial sponsored by MedImmune LLC

Keunpyo Kim: Employee: Employee of MedImmune LLC

Joseph Parker: Employee: Employee of MedImmune LLC

Kimmie McLaurin: Employee: Employee of MedImmune LLC

Xiao Tu: Employee: Employee of MedImmune LLC

Nestor Molfino: Employee: Employee of MedImmune LLC

The data from this trial was obtained from a randomized controlled clinical trial of an investigation product. No information regarding the investigational product is contained in this abstract.

MedImmune LLC, Gaithersberg, MD

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543